Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | EP300 | Q09472 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14306724 | 1.00 | MAPT (0.50) | MAPTGAABRD4CREBBPAR | |
| SCHEMBL7551415 | 1.00 | MAPT (0.50) | MAPTGAABRD4CREBBPAR | |
| SCHEMBL28561657 | 0.83 | CREBBP (0.49) | MAPTGAABRD4CREBBPAR | |
| SCHEMBL1550271 | 0.81 | MTNR1A (0.42) | MAPTGAAAHRPDK2NPC1 | |
| SCHEMBL30929595 | 0.81 | MTNR1A (0.42) | MAPTGAAAHRPDK2NPC1 | |
| SCHEMBL18292608 | 0.80 | MAPT (0.46) | MAPTGAABRD4CREBBPAR | |
| SCHEMBL7551246 | 0.80 | MAPT (0.46) | MAPTGAABRD4CREBBPAR | |
| SCHEMBL10406276 | 0.80 | MAPT (0.46) | MAPTGAABRD4CREBBPAR | |
| SCHEMBL18567158 | 0.80 | MAPT (0.46) | MAPTGAABRD4CREBBPAR | |
| SCHEMBL19663521 | 0.80 | MAPT (0.46) | MAPTGAABRD4CREBBPAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112724066-B | Dihalogen impurity in ziprasidone hydrochloride intermediate and preparation method thereof | 海南鑫开源医药科技有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-114369087-A | Synthesis and application of lactone analogue with indoline-2-ketone skeleton | 南开大学 | 2022-04-19 | — | — | CN | claimed |
| CN-112961150-A | Impurities in ziprasidone hydrochloride and preparation method thereof | 海南鑫开源医药科技有限公司 | 2021-06-15 | — | — | CN | claimed |
| CN-112778298-A | Impurities in ziprasidone hydrochloride and preparation method thereof | 海南鑫开源医药科技有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-112724066-A | Dihalogen impurity in ziprasidone hydrochloride intermediate and preparation method thereof | 海南鑫开源医药科技有限公司 | 2021-04-30 | — | — | CN | claimed |
| CN-109963851-A | The bicyclic pyridine compound of fusion and its purposes as ampa receptor regulator | 詹森药业有限公司 | 2019-07-02 | — | — | CN | claimed |
| CN-106459068-B | Novel compositions, uses and processes for their preparation | 皮梅拉股份有限公司 | 2019-01-22 | — | — | CN | claimed |
| CN-108349942-A | Indolin-2-one derivative for treating CNS and relevant disease | 豪夫迈·罗氏有限公司 | 2018-07-31 | — | — | CN | claimed |
| CN-107567452-A | Imidazopyrazine and pyrazolopyrimidine and their purposes as ampa receptor conditioning agent | 詹森药业有限公司 | 2018-01-09 | — | — | CN | claimed |
| CN-104910148-B | Aminotriazole(ATA) and pyridine and its as kinase inhibitor purposes | 西格诺药品有限公司 | 2017-06-27 | — | — | CN | claimed |
| CN-101679404-A | piperidine-amide derivatives | HOFFMANN LA ROCHE | 2010-03-24 | — | — | CN | claimed |
| CN-101033226-A | 1-furylmethyl-3-substituted indolin-2-one derivative | UNIV FUDAN (CN) | 2007-09-12 | — | — | CN | claimed |
| CN-1970556-A | 1-furfuryl-3-substituted Indolinyl-2-one derivative, its preparation method and uses | UNIV FUDAN (CN) | 2007-05-30 | — | — | CN | claimed |
| US-6468977-B1 | COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS | APOTEX INC. (CA) | 2002-10-22 | — | — | US | claimed |
| WO-2001090095-A1 | THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES | APOTEX INC. (CA) | 2001-11-29 | — | — | WO | claimed |
| JP-H09501913-A | — | — | 1997-02-25 | — | — | JP | claimed |
| EP-0738154-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | Abbott Laboratories (US) | 1996-10-23 | — | — | EP | claimed |
| EP-0738154-A4 | N-TERMINUS MODIFIED ANALOGS OF LHRH | ABBOTT LAB (US) | 1996-04-12 | — | — | EP | claimed |
| US-5502035-A | N-terminus modified analogs of LHRH | TAP HOLDINGS INC. (US) | 1996-03-26 | — | — | US | claimed |
| WO-1995004541-A1 | N-TERMINUS MODIFIED ANALOGS OF LHRH | ABBOTT LABORATORIES (US) | 1995-02-16 | — | — | WO | claimed |